Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Metabolism, diet and disease

Open Access Oral presentation

Beyond insulin: rethinking cellular metabolism

Craig B Thompson

  • Correspondence: Craig B Thompson

Author Affiliations

Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

BMC Proceedings 2012, 6(Suppl 3):O25  doi:10.1186/1753-6561-6-S3-O25


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/6/S3/O25


Published:1 June 2012

© 2012 Thompson; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral presentation

The latest cancer therapeutics are almost all inhibitors of oncogenes or their downstream mediators. With the exception of imatinib, most such drugs have been disappointing in the clinic. In contrast, existing successful cancer drugs have a therapeutic index because they render the consequences of oncogene activation selectively toxic to the cancer cell. A renewed focus on this type of approach appears warranted and should be considered.